Thousands of people have filed product liability claims after suffering serious and debilitating side effects allegedly associated with use of Levaquin. While Levaquin settlements have been announced in cases involving tendon ruptures, hundreds of claims involving peripheral neuropathy and aortic aneurysm/dissection remain to be litigated.
Hundreds of Levaquin lawsuits have been filed in U.S. courts on behalf of individuals who allegedly suffered peripheral neuropathy and other complications following use of the fluoroquinolone antibiotic. While there is no guarantee that any of these cases will result in a Levaquin settlement, the attorneys at Bernstein Liebhard LLP are confident that many plaintiffs will be able to obtain compensation for their alleged injuries. If you would like to join this growing litigation, please call our office at (888) 994-5118 to discuss your case with a member of our legal team.
The majority of claims currently involving Levaquin were filed on behalf of patients who allegedly developed a potentially debilitating form of nerve damage called peripheral neuropathy while taking the antibiotic. Mention of this condition was first added to the labels of all fluoroquinolone antibiotics in 2004. However, plaintiffs contend that the wording wrongly indicated that nerve damage from fluoroquinolones was both rare and temporary. It wasn’t until August 2013 that the drugs’ manufacturers revised their labels—at the behest of the U.S. Food & Drug Administration (FDA) — to state that fluoroquinolone-associated peripheral neuropathy could be permanent. The FDA also required the removal of language indicating that the disorder was a rare side effect.
In August 2016, all federally-filed peripheral neuropathy lawsuits involving Levaquin, Cipro and Avelox were centralized in a multidistrict litigation that is currently underway in the U.S. District Court, District of Minnesota. As of December 2016, the litigation included more than 700 cases. Hundreds of additional lawsuits are pending in state courts throughout the U.S.
A number of Levaquin claims have also been filed in U.S. courts on behalf of patients who allegedly experienced aortic aneurysm or aortic dissection while using the medication. This litigation is in its earliest stages, and no move has been made to centralize these claims.
So far, no Levaquin settlements have been announced in cases involving peripheral neuropathy or aortic injuries.
The Levaquin label was updated in 2008 to warn of an association with serious tendon injuries, including tendon ruptures. Eventually, thousands of lawsuits were filed on behalf of patients who had allegedly experienced these painful and disabling side effects. In 2008, federal claims involving Levaquin and tendon injuries were centralized in the District of Minnesota.
In November 2012, the Court disclosed that Levaquin settlements had been reached in 845 tendon injury claims. This represented about 25% of the cases pending in the federal litigation. In May of the following year, the Court reported that settlements had been reached in 1,182 of the 1,892 pending claims. Settlement talks were underway in another 153 Levaquin lawsuits.
Hundreds of additional Levaquin lawsuits had a been centralized in a multicounty litigation established in New Jersey Superior Court. In May 2013, it was reported that 898 of those cases were subject to dismissal due to Levaquin settlements.
Individuals who allegedly developed peripheral neuropathy or aortic injuries related to the use of Levaquin could be entitled to significant financial compensation as a part of any future settlement, including payment for medical bills, lost wages, disability and more. Bernstein Liebhard LLP currently represents a number of Levaquin plaintiffs, and our Firm continues to provide free, no-obligation case reviews to those interested in pursuing similar claims. To learn more, please call our office today at (888) 994-5118.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.